Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin Plus Cevostamab and Pomalidomide in RRMM
NCT07831122Phase 1Not yet recruiting
- Sponsor
- Canadian Myeloma Research Group
- Start
- Dec 2026
- Primary completion
- Jan 2033
- Countries
- 1
01
Overview
Phase 1, open-label trial of belantamab mafodotin and cevostamab in multiple myeloma (MM) (2 arms), sponsored by Canadian Myeloma Research Group. Primary endpoints: Recommended Phase 2 Dose at 9 weeks and Overall Response Rate at 24 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
belantamab mafodotincevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07831122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07831122.